ATAD2 in cancer: a pharmacologically challenging but tractable target

References

• Jeon J, Nim S, Teyra J, et al. A systematic approach to identify novel cancer drug targets using machine learning, inhibitor design and high-throughput screening. Genome Med. 2014;6:57.
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339:1546–1558.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Li M, Rayburn ER, et al. Oncogenes as novel targets for cancer therapy (part I): growth factors and protein tyrosine kinases. Am J Pharmacogenomics. 2005;5:173–190.
   PubMedGoogle Scholar
• Zhang Z, Li M, Rayburn ER, et al. Oncogenes as novel targets for cancer therapy (part II): intermediate signaling molecules. Am J Pharmacogenomics. 2005;5:247–257.
   PubMedGoogle Scholar
• Zhang Z, Li M, Rayburn ER, et al. Oncogenes as novel targets for cancer therapy (part III): transcription factors. Am J Pharmacogenomics. 2005;5:327–338.
   PubMedGoogle Scholar
• Zhang Z, Li M, Rayburn ER, et al. Oncogenes as novel targets for cancer therapy (part IV): regulators of the cell cycle and apoptosis. Am J Pharmacogenomics. 2005;5:397–407.
   PubMedGoogle Scholar
• Dang CV, Reddy EP, Shokat KM, et al. Drugging the ‘undruggable’ cancer targets. Nat Rev Cancer. 2017;17:502–508.
   PubMed Web of Science ®Google Scholar
• Lazo JS, Sharlow ER. Drugging undruggable molecular cancer targets. Annu Rev Pharmacol Toxicol. 2016;56:23–40.
   PubMed Web of Science ®Google Scholar
• Zhang ZY. Drugging the undruggable: therapeutic potential of targeting protein tyrosine phosphatases. Acc Chem Res. 2017;50:122–129.
   PubMed Web of Science ®Google Scholar
• Zhang JT, Liu JY. Drugging the “undruggable” DNA-binding domain of STAT3. Oncotarget. 2016;7:66324–66325.
   PubMed Web of Science ®Google Scholar
• Boussouar F, Jamshidikia M, Morozumi Y, et al. Malignant genome reprogramming by ATAD2. Biochim Biophys Acta. 2013;1829:1010–1014.
   PubMed Web of Science ®Google Scholar
• Ciro M, Prosperini E, Quarto M, et al. ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors. Cancer Res. 2009;69:8491–8498.
   PubMed Web of Science ®Google Scholar
• Vukovic S, Brennan PE, Huggins DJ. Exploring the role of water in molecular recognition: predicting protein ligandability using a combinatorial search of surface hydration sites. J Phys Condens Matter. 2016;28:344007.
   PubMed Web of Science ®Google Scholar
• Vidler LR, Brown N, Knapp S, et al. Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. J Med Chem. 2012;55:7346–7359.
   PubMed Web of Science ®Google Scholar
• Bamborough P, Chung CW, Demont EH, et al. A chemical probe for the ATAD2 bromodomain. Angew Chem Int Ed Engl. 2016;55:11382–11386.
   PubMed Web of Science ®Google Scholar
• Bamborough P, Chung CW, Furze RC, et al. Structure-based optimization of naphthyridones into potent ATAD2 bromodomain inhibitors. J Med Chem. 2015;58:6151–6178.
   PubMed Web of Science ®Google Scholar
• Chaikuad A, Petros AM, Fedorov O, et al. Structure-based approaches towards identification of fragments for the low-druggability ATAD2 bromodomain. Med Chem Commun. 2014;5:1843–1848.
   Google Scholar
• Cattaneo M, Morozumi Y, Perazza D, et al. Lessons from yeast on emerging roles of the ATAD2 protein family in gene regulation and genome organization. Mol Cells. 2014;37:851–856.
   PubMed Web of Science ®Google Scholar
• Hanson PI, Whiteheart SW. AAA+ proteins: have engine, will work. Nat Rev Mol Cell Biol. 2005;6:519–529.
   PubMed Web of Science ®Google Scholar
• Kedzierska S. [Structure, function and mechanisms of action of ATPases from the AAA superfamily of proteins]. Postepy Biochem. 2006;52:330–338.
   PubMedGoogle Scholar
• Snider J, Thibault G, Houry WA. The AAA+ superfamily of functionally diverse proteins. Genome Biol. 2008;9:216.
   PubMed Web of Science ®Google Scholar
• Snider J, Houry WA. AAA+ proteins: diversity in function, similarity in structure. Biochem Soc Trans. 2008;36:72–77.
   PubMed Web of Science ®Google Scholar
• Pollack JR, Sorlie T, Perou CM, et al. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA. 2002;99:12963–12968.
   PubMed Web of Science ®Google Scholar
• Leachman NT, Brellier F, Ferralli J, et al. ATAD2B is a phylogenetically conserved nuclear protein expressed during neuronal differentiation and tumorigenesis. Dev Growth Differ. 2010;52:747–755.
   PubMed Web of Science ®Google Scholar
• Altintas DM, Shukla MS, Goutte-Gattat D, et al. Direct cooperation between androgen receptor and E2F1 reveals a common regulation mechanism for androgen-responsive genes in prostate cells. Mol Endocrinol. 2012;26:1531–1541.
   PubMedGoogle Scholar
• Zou JX, Guo L, Revenko AS, et al. Androgen-induced coactivator ANCCA mediates specific androgen receptor signaling in prostate cancer. Cancer Res. 2009;69:3339–3346.
   PubMed Web of Science ®Google Scholar
• Caron C, Lestrat C, Marsal S, et al. Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers. Oncogene. 2010;29:5171–5181.
   PubMed Web of Science ®Google Scholar
• Dhalluin C, Carlson JE, Zeng L, et al. Structure and ligand of a histone acetyltransferase bromodomain. Nature. 1999;399:491–496.
   PubMed Web of Science ®Google Scholar
• Owen DJ, Ornaghi P, Yang JC, et al. The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase gcn5p. Embo J. 2000;19:6141–6149.
   PubMed Web of Science ®Google Scholar
• Revenko AS, Kalashnikova EV, Gemo AT, et al. Chromatin loading of E2F-MLL complex by cancer-associated coregulator ANCCA via reading a specific histone mark. Mol Cell Biol. 2010;30:5260–5272.
   PubMed Web of Science ®Google Scholar
• Morozumi Y, Boussouar F, Tan M, et al. Atad2 is a generalist facilitator of chromatin dynamics in embryonic stem cells. J Mol Cell Biol. 2016;8:349–362.
   PubMed Web of Science ®Google Scholar
• Mjelle R, Hegre SA, Aas PA, et al. Cell cycle regulation of human DNA repair and chromatin remodeling genes. DNA Repair (Amst). 2015;30:53–67.
   PubMed Web of Science ®Google Scholar
• Liu J, Lee W, Jiang Z, et al. Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. Genome Res. 2012;22:2315–2327.
   PubMed Web of Science ®Google Scholar
• Wrzeszczynski KO, Varadan VByrnes J, et al. Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer. Plos One. 2011;6:e28503.
   PubMed Web of Science ®Google Scholar
• Hsia EY, Kalashnikova EV, Revenko AS, et al. Deregulated E2F and the AAA+ coregulator ANCCA drive proto-oncogene ACTR/AIB1 overexpression in breast cancer. Mol Cancer Res. 2010;8:183–193.
   PubMed Web of Science ®Google Scholar
• Zou JX, Revenko AS, Li LB, et al. ANCCA, an estrogen-regulated AAA+ ATPase coactivator for ERalpha, is required for coregulator occupancy and chromatin modification. Proc Natl Acad Sci USA. 2007;104:18067–18072.
   PubMed Web of Science ®Google Scholar
• Duan Z, Zou JX, Yang P, et al. Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate via MLL histone methylase complex. Prostate. 2013;73:455–466.
   PubMed Web of Science ®Google Scholar
• Kalashnikova EV, Revenko AS, Gemo AT, et al. ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-MYB and EZH2. Cancer Res. 2010;70:9402–9412.
   PubMed Web of Science ®Google Scholar
• Krakstad C, Tangen IL, Hoivik EA, et al. ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma. Oncotarget. 2015;6:28440–28452.
   PubMed Web of Science ®Google Scholar
• Shang P, Meng F, Liu Y, et al. Overexpression of ANCCA/ATAD2 in endometrial carcinoma and its correlation with tumor progression and poor prognosis. Tumour Biol. 2015;36:4479–4485.
   PubMedGoogle Scholar
• Raeder MB, Birkeland E, Trovik J, et al. Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. PLoS One. 2013;8:e54873.
   PubMed Web of Science ®Google Scholar
• Wu G, Lu X, Wang Y, et al. Epigenetic high regulation of ATAD2 regulates the Hh pathway in human hepatocellular carcinoma. Int J Oncol. 2014;45:351–361.
   PubMed Web of Science ®Google Scholar
• Koo SJ, Fernandez-Montalvan AE, Badock V, et al. ATAD2 is an epigenetic reader of newly synthesized histone marks during DNA replication. Oncotarget. 2016. DOI:10.18632/oncotarget.11855
   Web of Science ®Google Scholar
• Lu WJ, Chua MS, So SK. Suppression of ATAD2 inhibits hepatocellular carcinoma progression through activation of p53- and p38-mediated apoptotic signaling. Oncotarget. 2015;6:41722–41735.
   PubMed Web of Science ®Google Scholar
• Huang Q, Lin B, Liu H, et al. RNA-Seq analyses generate comprehensive transcriptomic landscape and reveal complex transcript patterns in hepatocellular carcinoma. PLoS One. 2011;6:e26168.
   PubMed Web of Science ®Google Scholar
• Hong S, Bi M, Yan Z, et al. Silencing of ATPase family AAA domain-containing protein 2 inhibits migration and invasion of colorectal cancer cells. Neoplasma. 2016;63:846–855.
   PubMed Web of Science ®Google Scholar
• Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005;365:671–679.
   PubMed Web of Science ®Google Scholar
• De Angelis PM, Svendsrud DH, Kravik KL, et al. Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol Cancer. 2006;5:20.
   PubMed Web of Science ®Google Scholar
• Murakami H, Ito S, Tanaka H, et al. Establishment of new intraperitoneal paclitaxel-resistant gastric cancer cell lines and comprehensive gene expression analysis. Anticancer Res. 2013;33:4299–4307.
   PubMed Web of Science ®Google Scholar
• Zou JX, Duan Z, Wang J, et al. Kinesin family deregulation coordinated by bromodomain protein ANCCA and histone methyltransferase MLL for breast cancer cell growth, survival, and tamoxifen resistance. Mol Cancer Res. 2014;12:539–549.
   PubMed Web of Science ®Google Scholar
• Salvesen HB, Carter SL, Mannelqvist M, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci USA. 2009;106:4834–4839.
   PubMed Web of Science ®Google Scholar
• van ‘T Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–536.
   PubMed Web of Science ®Google Scholar
• Vidalin O, Muslmani M, Estienne C, et al. In vivo target validation using gene invalidation, RNA interference and protein functional knockout models: it is the time to combine. Curr Opin Pharmacol. 2009;9:669–676.
   PubMed Web of Science ®Google Scholar
• Colombo R, Moll J. Target validation to biomarker development: focus on RNA interference. Mol Diagn Ther. 2008;12:63–70.
   PubMed Web of Science ®Google Scholar
• Natt F. siRNAs in drug discovery: target validation and beyond. Curr Opin Mol Ther. 2007;9:242–247.
   PubMedGoogle Scholar
• Luo Y, Ye GY, Qin SL, et al. ATAD2 overexpression identifies colorectal cancer patients with poor prognosis and drives proliferation of cancer cells. Gastroenterol Res Pract. 2015;2015:936564.
   PubMedGoogle Scholar
• Wu G, Liu H, He H, et al. miR-372 down-regulates the oncogene ATAD2 to influence hepatocellular carcinoma proliferation and metastasis. BMC Cancer. 2014;14:107.
   PubMed Web of Science ®Google Scholar
• Wan WN, Zhang YX, Wang XM, et al. ATAD2 is highly expressed in ovarian carcinomas and indicates poor prognosis. Asian Pac J Cancer Prev. 2014;15:2777–2783.
   PubMedGoogle Scholar
• Zheng L, Li T, Zhang Y, et al. Oncogene ATAD2 promotes cell proliferation, invasion and migration in cervical cancer. Oncol Rep. 2015;33:2337–2344.
   PubMed Web of Science ®Google Scholar
• Gashaw I, Ellinghaus P, Sommer A, et al. What makes a good drug target? Drug Discov Today. 2011;16:1037–1043.
   PubMed Web of Science ®Google Scholar
• Gashaw I, Ellinghaus P, Sommer A, et al. What makes a good drug target? Drug Discov Today. 2012;17 Suppl:S2–S30.
   Web of Science ®Google Scholar
• Henrich S, Salo-Ahen OM, Huang B, et al. Computational approaches to identifying and characterizing protein binding sites for ligand design. J Mol Recognit. 2010;23:209–219.
   PubMed Web of Science ®Google Scholar
• Firestone AJ, Weinger JS, Maldonado M, et al. Small-molecule inhibitors of the AAA+ ATPase motor cytoplasmic dynein. Nature. 2012;484:125–129.
   PubMed Web of Science ®Google Scholar
• Muller S, Filippakopoulos P, Knapp S. Bromodomains as therapeutic targets. Expert Rev Mol Med. 2011;13:e29.
   PubMed Web of Science ®Google Scholar
• Poncet-Montange G, Zhan Y, Bardenhagen JP, et al. Observed bromodomain flexibility reveals histone peptide- and small molecule ligand-compatible forms of ATAD2. Biochem J. 2015;466:337–346.
   PubMed Web of Science ®Google Scholar
• Filippakopoulos P, Picaud S, Mangos M, et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell. 2012;149:214–231.
   PubMed Web of Science ®Google Scholar
• Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature. 2010;468:1067–1073.
   PubMed Web of Science ®Google Scholar
• Nakagawa A, Adams CE, Huang Y, et al. Selective and reversible suppression of intestinal stem cell differentiation by pharmacological inhibition of BET bromodomains. Sci Rep. 2016;6:20390.
   PubMed Web of Science ®Google Scholar
• Nicodeme E, Jeffrey KL, Schaefer U, et al. Suppression of inflammation by a synthetic histone mimic. Nature. 2010;468:1119–1123.
   PubMed Web of Science ®Google Scholar
• Xu M, Unzue A, Dong J, et al. Discovery of CREBBP bromodomain inhibitors by high-throughput docking and hit optimization guided by molecular dynamics. J Med Chem. 2016;59:1340–1349.
   PubMed Web of Science ®Google Scholar
• Harner MJ, Chauder BA, Phan J, et al. Fragment-based screening of the bromodomain of ATAD2. J Med Chem. 2014;57:9687–9692.
   PubMed Web of Science ®Google Scholar
• Hajduk PJ, Huth JR, Fesik SW. Druggability indices for protein targets derived from NMR-based screening data. J Med Chem. 2005;48:2518–2525.
   PubMed Web of Science ®Google Scholar
• Demont EH, Chung CW, Furze RC, et al. Fragment-based discovery of low-micromolar ATAD2 bromodomain inhibitors. J Med Chem. 2015;58:5649–5673.
   PubMed Web of Science ®Google Scholar
• Elkaim J, Castroviejo M, Bennani D, et al. First identification of small-molecule inhibitors of Pontin by combining virtual screening and enzymatic assay. Biochem J. 2012;443:549–559.
   PubMed Web of Science ®Google Scholar
• Chou TF, Brown SJ, Minond D, et al. Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. Proc Natl Acad Sci USA. 2011;108:4834–4839.
   PubMed Web of Science ®Google Scholar
• Goller T, Seibold UK, Kremmer E, et al. Atad3 function is essential for early post-implantation development in the mouse. PLoS One. 2013;8:e54799.
   PubMed Web of Science ®Google Scholar
• Issop L, Fan J, Lee S, et al. Mitochondria-associated membrane formation in hormone-stimulated Leydig cell steroidogenesis: role of ATAD3. Endocrinology. 2015;156:334–345.
   PubMed Web of Science ®Google Scholar
• Li S, Yao Y, Xu R, et al. ATAD3 is a limiting factor in mitochondrial biogenesis and adipogenesis of white adipocyte-like 3T3-L1 cells. Mol Cell Biol. 2014. DOI:10.1128/MCB.01170-13
   Google Scholar
• Li S, Rousseau D. [ATAD3, a vital membrane-bound mitochondrial ATPase involved in tumor progression]. Med Sci (Paris). 2011;27:1089–1095.
   PubMed Web of Science ®Google Scholar
• Li S, Rousseau D. ATAD3, a vital membrane bound mitochondrial ATPase involved in tumor progression. J Bioenerg Biomembr. 2012;44:189–197.
   PubMed Web of Science ®Google Scholar
• Maleva Kostovska I, Wang J, Bogdanova N, et al. Rare ATAD5 missense variants in breast and ovarian cancer patients. Cancer Lett. 2016;376:173–177.
   PubMed Web of Science ®Google Scholar
• Ghosh A, Ghosh S, Dasgupta D, et al. Hepatitis B virus X protein upregulates hELG1/ATAD5 expression through E2F1 in hepatocellular carcinoma. Int J Biol Sci. 2016;12:30–41.
   PubMed Web of Science ®Google Scholar
• Bell DW, Sikdar N, Lee KY, et al. Predisposition to cancer caused by genetic and functional defects of mammalian Atad5. PLoS Genet. 2011;7:e1002245.
   PubMed Web of Science ®Google Scholar
• Kubota T, Myung K, Donaldson AD. Is PCNA unloading the central function of the Elg1/ATAD5 replication factor C-like complex? Cell Cycle. 2013;12:2570–2579.
   PubMed Web of Science ®Google Scholar
• Lee KY, Fu H, Aladjem MI, et al. ATAD5 regulates the lifespan of DNA replication factories by modulating PCNA level on the chromatin. J Cell Biol. 2013;200:31–44.
   PubMed Web of Science ®Google Scholar
• La Thangue NB, Kerr DJ. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol. 2011;8:587–596.
   PubMed Web of Science ®Google Scholar
• Contasta I, Berghella AM, Lattanzio R, et al. Novel prognostic biomarkers for personalized cancer treatment. Cancer Immunol. 2015; Springer Berlin Heidelberg; 2014:35–54.
   Google Scholar
• Rossi A, Torri V, Garassino MC, et al. The impact of personalized medicine on survival: comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers. Cancer Treat Rev. 2014;40:485–494.
   PubMed Web of Science ®Google Scholar
• Welch DR, Rinker-Schaeffer CW. What defines a useful marker of metastasis in human cancer? J Natl Cancer Inst. 1999;91:1351–1353.
   PubMedGoogle Scholar
• Wu SY, Lopez-Berestein G, Calin GA, et al. RNAi therapies: drugging the undruggable. Sci Transl Med. 2014;6:240ps7.
   PubMed Web of Science ®Google Scholar
• Yan R, Hallam A, Stockley PG, et al. Oncogene dependency and the potential of targeted RNAi-based anti-cancer therapy. Biochem J. 2014;461:1–13.
   PubMed Web of Science ®Google Scholar
• Yang WQ, Zhang Y. RNAi-mediated gene silencing in cancer therapy. Expert Opin Biol Ther. 2012;12:1495–1504.
   PubMed Web of Science ®Google Scholar